[{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"f180fa4a-86d7-4c90-bf6f-101d2893b440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05689021","created_at":"2023-01-18T14:59:57.536Z","updated_at":"2024-07-02T16:35:04.068Z","phase":"Phase 2","brief_title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","source_id_and_acronym":"NCT05689021","lead_sponsor":"Mayo Clinic","biomarkers":" SPOP","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-13"},{"id":"ca9c53ec-c832-4b1c-9e81-bef149f09451","acronym":"","url":"https://clinicaltrials.gov/study/NCT04060394","created_at":"2021-01-18T19:54:03.680Z","updated_at":"2024-07-02T16:35:09.013Z","phase":"Phase 1/2","brief_title":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC","source_id_and_acronym":"NCT04060394","lead_sponsor":"Laekna Limited","biomarkers":" PIK3CA • PTEN • BRCA","pipe":" | ","alterations":" PTEN mutation • BRCA mutation","tags":["PIK3CA • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • afuresertib (LAE002) • LAE001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 09/13/2019","start_date":" 09/13/2019","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-04-18"},{"id":"ef5f595b-9e34-4513-9b8d-50b1aa6a34da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03176381","created_at":"2021-01-18T15:39:48.196Z","updated_at":"2024-07-02T16:35:29.387Z","phase":"","brief_title":"Tissue Predictors of Abiraterone Benefit","source_id_and_acronym":"NCT03176381","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" YAP1 • PCNA","pipe":" | ","alterations":" YAP1 positive • PCNA expression","tags":["YAP1 • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YAP1 positive • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-11-14"},{"id":"65af3a39-ef1d-49dc-a8f5-a6e260b5808e","acronym":"PEACE-1","url":"https://clinicaltrials.gov/study/NCT01957436","created_at":"2021-01-18T08:53:11.774Z","updated_at":"2024-07-02T16:35:29.880Z","phase":"Phase 3","brief_title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","source_id_and_acronym":"NCT01957436 - PEACE-1","lead_sponsor":"UNICANCER","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • zoledronic acid"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1173","initiation":"Initiation: 11/13/2013","start_date":" 11/13/2013","primary_txt":" Primary completion: 08/18/2021","primary_completion_date":" 08/18/2021","study_txt":" Completion: 12/01/2032","study_completion_date":" 12/01/2032","last_update_posted":"2023-11-08"},{"id":"151866cc-e867-4d02-9e28-ed8aca2cafdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03348670","created_at":"2023-08-31T18:07:58.429Z","updated_at":"2024-07-02T16:35:33.486Z","phase":"Phase 2/3","brief_title":"Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","source_id_and_acronym":"NCT03348670","lead_sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • Orgovyx (relugolix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 08/18/2023","start_date":" 08/18/2023","primary_txt":" Primary completion: 05/18/2024","primary_completion_date":" 05/18/2024","study_txt":" Completion: 05/28/2024","study_completion_date":" 05/28/2024","last_update_posted":"2023-10-16"},{"id":"e61a842e-3393-4ae3-9685-c52db2616f42","acronym":"4CAST","url":"https://clinicaltrials.gov/study/NCT04947189","created_at":"2021-07-01T14:54:41.667Z","updated_at":"2024-07-02T16:35:33.448Z","phase":"Phase 1b","brief_title":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT04947189 - 4CAST","lead_sponsor":"St Vincent's Hospital, Sydney","biomarkers":" HER-2 • PGR • AR","pipe":" | ","alterations":" HR positive • HER-2 negative • AR positive • EGFR positive","tags":["HER-2 • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • AR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • dexamethasone • seviteronel (INO-464)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-16"},{"id":"c88bd8d2-1222-406c-ba31-c677f4047764","acronym":"ASCLEPIuS","url":"https://clinicaltrials.gov/study/NCT04194554","created_at":"2021-07-05T17:26:59.721Z","updated_at":"2024-07-02T16:35:37.018Z","phase":"Phase 1/2","brief_title":"A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer","source_id_and_acronym":"NCT04194554 - ASCLEPIuS","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" DRD","pipe":" | ","alterations":" DDR • DRD","tags":["DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-09-14"},{"id":"a436e6fd-356f-49de-8a27-97d65692d9e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03236688","created_at":"2021-07-07T15:54:07.425Z","updated_at":"2024-07-02T16:36:02.923Z","phase":"","brief_title":"Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)","source_id_and_acronym":"NCT03236688","lead_sponsor":"Exosome Diagnostics, Inc.","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7 • AR splice variant 7 negative","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7 • AR splice variant 7 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-10-06"},{"id":"4f6d93b4-be3f-49d8-99d0-e1e8eb726d81","acronym":"PSMA-BAT","url":"https://clinicaltrials.gov/study/NCT04424654","created_at":"2021-07-05T17:30:35.370Z","updated_at":"2024-07-02T16:36:06.125Z","phase":"Phase 2","brief_title":"Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy","source_id_and_acronym":"NCT04424654 - PSMA-BAT","lead_sponsor":"Hospital Sirio-Libanes","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2022-08-03"},{"id":"af2ca646-b71d-4b28-aa4e-b1494c15df54","acronym":"EXPLORE","url":"https://clinicaltrials.gov/study/NCT04268628","created_at":"2021-01-20T21:59:58.049Z","updated_at":"2024-07-02T16:36:19.009Z","phase":"","brief_title":"A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol","source_id_and_acronym":"NCT04268628 - EXPLORE","lead_sponsor":"Janssen-Cilag Farmaceutica Ltda.","biomarkers":" HSD3B1","pipe":"","alterations":" ","tags":["HSD3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 11/16/2020","primary_completion_date":" 11/16/2020","study_txt":" Completion: 11/16/2020","study_completion_date":" 11/16/2020","last_update_posted":"2021-12-31"},{"id":"935757e6-fc4c-43e2-b81d-6a4188538dfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01842321","created_at":"2021-01-18T08:12:38.375Z","updated_at":"2024-07-02T16:36:34.231Z","phase":"Phase 2","brief_title":"Abiraterone Acetate in Molecular Apocrine Breast Cancer","source_id_and_acronym":"NCT01842321","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 07/15/2015","primary_completion_date":" 07/15/2015","study_txt":" Completion: 07/04/2018","study_completion_date":" 07/04/2018","last_update_posted":"2021-02-23"},{"id":"a0ae763d-fd7e-4a3a-8b7f-b5e9a545ee4c","acronym":"ABIGENE","url":"https://clinicaltrials.gov/study/NCT01858441","created_at":"2021-01-18T08:18:24.935Z","updated_at":"2024-07-02T16:36:37.840Z","phase":"","brief_title":"Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate","source_id_and_acronym":"NCT01858441 - ABIGENE","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" CYP17A1 • SLCO2B1","pipe":"","alterations":" ","tags":["CYP17A1 • SLCO2B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 09/06/2020","primary_completion_date":" 09/06/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2020-12-04"},{"id":"64dc377c-8fcd-432d-95e8-37fc6bb1ae8c","acronym":"PROSABI","url":"https://clinicaltrials.gov/study/NCT02787837","created_at":"2021-01-18T13:40:35.180Z","updated_at":"2024-07-02T16:36:50.956Z","phase":"","brief_title":"PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.","source_id_and_acronym":"NCT02787837 - PROSABI","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN loss","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Unknown status","enrollment":" Enrollment 220","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"74bb0dc5-6670-4a97-bed0-b1c45b0dfe37","acronym":"CLARITY-01","url":"https://clinicaltrials.gov/study/NCT02580448","created_at":"2021-01-18T12:30:49.015Z","updated_at":"2024-07-02T16:37:03.253Z","phase":"Phase 1/2","brief_title":"CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)","source_id_and_acronym":"NCT02580448 - CLARITY-01","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-02-01"},{"id":"25170b14-2ea2-49b0-acfc-f00d60de235f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02130700","created_at":"2021-01-18T09:53:00.309Z","updated_at":"2024-07-02T16:37:10.952Z","phase":"Phase 2","brief_title":"Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer","source_id_and_acronym":"NCT02130700","lead_sponsor":"Innocrin Pharmaceutical","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • seviteronel (INO-464)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-05-07"},{"id":"1a7ccaaf-9044-4f2f-ae35-54a15ea11dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393730","created_at":"2021-01-18T05:43:26.209Z","updated_at":"2024-07-02T16:37:13.008Z","phase":"Phase 2","brief_title":"Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT01393730","lead_sponsor":"Mary-Ellen Taplin, MD","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR T878A • AR amplification","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR T878A • AR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 03/15/2017","study_completion_date":" 03/15/2017","last_update_posted":"2018-03-15"},{"id":"1f7a7f14-1d9e-49c2-8bc0-4b64dc4f57f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02928432","created_at":"2021-01-18T14:23:00.444Z","updated_at":"2024-07-02T16:37:26.171Z","phase":"Phase 2","brief_title":"SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone","source_id_and_acronym":"NCT02928432","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2017-01-27"},{"id":"097144f2-d5ad-4a3f-ae45-f4911e82c967","acronym":"CRUK-CR9304-21","url":"https://clinicaltrials.gov/study/NCT00755885","created_at":"2021-01-18T02:51:21.472Z","updated_at":"2024-07-02T16:37:26.210Z","phase":"Phase 1/2","brief_title":"Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT00755885 - CRUK-CR9304-21","lead_sponsor":"Cancer Research UK","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 06/04/2016","primary_completion_date":" 06/04/2016","study_txt":" Completion: 06/04/2016","study_completion_date":" 06/04/2016","last_update_posted":"2017-01-26"}]